---
title: "Intellectual Property | Lionheart Longevity Investor Relations"
description: "Lionheart Health intellectual property summary: issued, pending, in-process, licensed and optioned patents and claims."
url: https://investors.lionheartlongevity.com/science/intellectual-property
---

Science

# Intellectual Property

Lionheart Health holds commercialization and license rights to its core Leonhardt Ventures portfolio, supplemented by third-party licensed and optioned technologies.

Patent and application entries

63

Issued claims (owned, licensed and optioned)

518

Aggregate issued, proposed and estimated claims

1,133

As of October 9, 2026

## Portfolio summary

| Portfolio / status                                    | Patents / applications           | Claims          |
| ----------------------------------------------------- | -------------------------------- | --------------- |
| IssuedCore Leonhardt portfolio                        | 18 patents                       | 301 issued      |
| PendingPublished applications                         | 8 applications                   | 135 proposed    |
| In processAnnounced filings and prepared applications | 24 entries                       | 480 estimated   |
| LicensedSchuler cancer technologies                   | 8 issued patents                 | 137 issued      |
| LicensedStangl Klotho-expressing stem cells           | 2 issued grants; 1 patent family | 40 issued       |
| OptionedSchuler muscle and neurocode technologies     | 3 issued patents                 | 40 issued       |
| Combined working inventory                            | 63 entries                       | 1,133 aggregate |

Issued-claim subtotal: 518, including 478 within disclosed commercial/licensed portfolios and 40 associated with options.

## What the portfolio covers

### Bioelectric control of regenerative proteins

Programmed electrical signals intended to increase or decrease the body’s production or release of proteins involved in repair, inflammation and healthy aging, including Klotho, follistatin, BDNF and SIRT6.

### Healthspan and organ function

Stimulation systems and treatment methods aimed at supporting muscle, brain, kidney, cardiovascular and other tissue functions.

### Regenerative aesthetics

Technologies addressing skin repair, collagen-related signaling and tissue elasticity, with application-stage approaches for hair regeneration and repigmentation.

### Regenerative cells and biologics

Klotho-producing stem cells and combinations of electrical stimulation with cells, peptides, exosomes and nutrient hydrogels.

### Targeted delivery systems

Devices and proposed platforms designed to place, maintain, replenish or control regenerative materials near selected tissues or organs.

### Cancer and biological electrical signals

Licensed technologies intended to record and modify cancer-cell electrical signals or promote cancer-cell death, alongside optioned systems for muscle control and responsive neurocode therapies.

Lionheart Health’s intellectual property portfolio supports its strategy of combining programmable bioelectric stimulation, controlled protein expression, regenerative biologics and targeted delivery for healthspan longevity, regenerative aesthetics and biological organ regeneration. Issued patents provide the foundation for protection, while pending applications and filings in development represent potential future coverage.

Disclosure

Protection applies to the specific combinations and methods described in granted claims. Pending and prepared applications represent proposed future coverage; patents do not establish that a treatment is clinically effective or approved.

Totals include overlapping claims and development estimates and do not represent 1,133 distinct enforceable rights.